Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
European Journal of Applied Physiology
|
August 12, 2006
Intramyocellular lipid stores increase markedly in athletes after 1.5 days lipid supplementation and are utilized during exercise in proportion to their content
Monica Zehnder, Emanuel R Christ, Michael Ith, et al.
Clinical Nuclear Medicine
|
June 20, 2020
Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging
Kwadwo Antwi, Matthias Hepprich, Natasha A Müller, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
April 6, 2002
Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus
Emanuel R Christ, Paul V Carroll, Elaine Albany, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
April 17, 2008
Effect of GH on human skeletal muscle lipid metabolism in GH deficiency
Roman Trepp, Martin Flück, Christoph Stettler, et al.
European Journal of Endocrinology
|
February 25, 2006
Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study
Emanuel R Christ, Michael H Cummings, Michael Stolinski, et al.
JAMA Oncology
|
February 15, 2019
Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis
Reto M Kaderli, Marko Spanjol, Attila Kollár, et al.
The Cochrane Database of Systematic Reviews
|
November 25, 2021
Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis
Martin A Walter, Cédric Nesti, Marko Spanjol, et al.
EJNMMI Research
|
April 6, 2024
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [<sup>177</sup>Lu]Lu-PP-F11N in humans: the lumed phase 0b study
Christof Rottenburger, Michael Hentschel, Markus Fürstner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 15, 2019
Cholecystokinin 2 Receptor Agonist <sup>177</sup>Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study
Christof Rottenburger, Guillaume P Nicolas, Lisa McDougall, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
European Journal of Applied Physiology
|
August 12, 2006
Intramyocellular lipid stores increase markedly in athletes after 1.5 days lipid supplementation and are utilized during exercise in proportion to their content
Monica Zehnder, Emanuel R Christ, Michael Ith, et al.
Clinical Nuclear Medicine
|
June 20, 2020
Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging
Kwadwo Antwi, Matthias Hepprich, Natasha A Müller, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
April 6, 2002
Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus
Emanuel R Christ, Paul V Carroll, Elaine Albany, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
April 17, 2008
Effect of GH on human skeletal muscle lipid metabolism in GH deficiency
Roman Trepp, Martin Flück, Christoph Stettler, et al.
European Journal of Endocrinology
|
February 25, 2006
Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study
Emanuel R Christ, Michael H Cummings, Michael Stolinski, et al.
JAMA Oncology
|
February 15, 2019
Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis
Reto M Kaderli, Marko Spanjol, Attila Kollár, et al.
The Cochrane Database of Systematic Reviews
|
November 25, 2021
Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis
Martin A Walter, Cédric Nesti, Marko Spanjol, et al.
EJNMMI Research
|
April 6, 2024
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [<sup>177</sup>Lu]Lu-PP-F11N in humans: the lumed phase 0b study
Christof Rottenburger, Michael Hentschel, Markus Fürstner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 15, 2019
Cholecystokinin 2 Receptor Agonist <sup>177</sup>Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study
Christof Rottenburger, Guillaume P Nicolas, Lisa McDougall, et al.
Page
of 4